Filing Flows › Biocryst Pharmaceuticals (BCRX) › Stock forecast & fair value
Biocryst Pharmaceuticals (BCRX) stock forecast and price target
Biocryst Pharmaceuticals (BCRX) trades at $7.69. 11 analysts' median price target is $17.00 (+121%), from $11.00 to $32.00.
Biocryst Pharmaceuticals' latest quarter
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for BCRX stock?
The median of 11 analysts' 12-month targets is $17.00, +121% from $7.69; the range is $11.00 to $32.00. The average rating is none.
Does Biocryst Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is BCRX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.